Bidirectional Relationship Between Primary Sj ögren's Syndrome and Non- Hodgkin's Lymphoma: A Nationwide Population-based Study.

CONCLUSION: This nationwide population-based study is the first study to report a bidirectional relationship between pSS and NHL. Our findings may suggest being alert for the patients with pSS or NHL who have early signs of the other disease in the clinical care. The underlying mechanisms of the bidirectional relationship merit further investigation. PMID: 31941803 [PubMed - as supplied by publisher]
Source: J Rheumatol - Category: Rheumatology Authors: Tags: J Rheumatol Source Type: research

Related Links:

Reena Goswami1, Gayatri Subramanian2, Liliya Silayeva1, Isabelle Newkirk1, Deborah Doctor1, Karan Chawla2, Saurabh Chattopadhyay2, Dhyan Chandra3, Nageswararao Chilukuri1 and Venkaiah Betapudi1,4* 1Neuroscience Branch, Research Division, United States Army Medical Research Institute of Chemical Defense, Aberdeen, MD, United States 2Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States 3Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States 4Department of Physiology and Biophysics, Case Western Reserve University, Clev...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Discussion In this section, we discuss the mechanisms responsible for lymphomagenesis in the various inborn errors of immunity and provide an overview of the treatment. Defects in Immune Responses That Predispose to Lymphomagenesis in PIDDs The complex immune mechanisms and their interplay that predisposes to neoplastic transformation of B or T cells and development of lymphomas in PIDD patients has not been fully elucidated. However, it is expected that the etiology in most cases is multifactorial and related to a dynamic regulation of immune response and environmental triggers (Figure 3). An underlying intrinsic susce...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Authors: Ben-Eli H, Aframian DJ, Ben-Chetrit E, Mevorach D, Kleinstern G, Paltiel O, Solomon A Abstract Objectives: To assess whether there are shared exposures associated with Sjogren's syndrome (SS), dry eye syndrome (DES), and B-cell non-Hodgkin lymphoma (B-NHL), in order to determine whether they are etiologically related. Methods: In a clinic-based case-control study, 702 participants (91 SS, 120 DES, 211 (age and sex frequency-matched) controls, and 280 B-NHL cases) were recruited and interviewed regarding exposures, medical history, and family history. Results: Female predominance was noted in SS (ra...
Source: Journal of Immunology Research - Category: Allergy & Immunology Tags: J Immunol Res Source Type: research
Conclusion: aTac- BEAM appears to be safe as an ASCT conditioning regimen for PTCL with no increased toxicity as compared to the historical toxicities seen with BEAM alone in this patient population (D'Amore 2012 J of Clin Onc). The dose level 0.6mCi/kg will likely be the recommended phase II dose. An expanded phase is planned to evaluate the efficacy of this regimen followed by a randomized trial of BEAM alone plus a combination of aTac- BEAM.Figure 1.DisclosuresHerrera: Seattle Genetics: Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Immune Design: Researc...
Source: Blood - Category: Hematology Authors: Tags: 731. Clinical Autologous Transplantation: Results: Autologous Transplantation: Clonal Hematopoiesis, Microbiota, AML, NHL, and Autoimmune Diseases Source Type: research
Conclusions:The incidence of t-MN is increasing as more patients survive their primary cancers. It is quite important to get further knowledge on the molecular biology of the group of therapy-related disorders not only for a better diagnostic and classification criteria, which may help in selecting individualized treatments, but also to investigate potential chemopreventive strategies.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - Category: Hematology Authors: Tags: 637. Myelodysplastic Syndromes-Clinical Studies Source Type: research
Conclusions: LEO is a large and diverse cohort of newly diagnosed NHL patients and the first two years of enrollment reflects the broader United States NHL population. Enrollment is ongoing. This unique resource will enable examination of the interactions among a broad array of clinical and molecular factors and their impact on multiple outcomes, to improve prognostication, identify new approaches to improve outcomes and survivorship, and facilitate clinical trials using this infrastructure.DisclosuresFlowers: Acerta: Research Funding; Pharmacyclics/ Janssen: Consultancy; OptumRx: Consultancy; Janssen Pharmaceutical: Resea...
Source: Blood - Category: Hematology Authors: Tags: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Retrospective/Observational Studies: Poster I Source Type: research
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy and accounts for the majority of aggressive non-Hodgkin lymphoma cases in the US.   While it is a curable disease with significant success from rituximab and CHOP chemotherapeutic treatment, a significant minority of patients with advanced stage disease and clinical risk factors are in need of alternative treatment strategies.Scientists at NCI ’sLymphoid Malignancies Branch, have developed a novel stapled-peptide that specifically targets the linear polyubiquitin chain assembly complex (LUBAC), a pathway involved in NF- κB activat...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Researchers at the National Cancer Institute (NCI) have developed antibodies that selectively target IL-7R α, a major driver of T-cell derived ALL (T-ALL) and an important therapeutic target for a range of diseases. The antibodies mediate leukemic cell killing through antibody-dependent cellular cytotoxicity (ADCC) and cause a significant reduction in T-ALL cell burden when administered in a xenograft m ouse model harboring patient derived leukemia. Researchers seek licensing and/or co-development research collaborations for further development of these antibodies.NIH Ref. No.: E-247-2015Advantages: • ...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
CONCLUSION: Poor response against pneumococcal vaccines increases the susceptibility of respiratory diseases in these patients. In patients with NHL treated with RTX, the benefits achieved with IVIg replacement for the control of recurrent infectious diseases is of paramount importance. Clinicians dealing with monoclonal antibodies against cancer therapy, especially RTX, should be aware of the increasing risks for symptomatic induced hypogammaglobulinemia and respiratory infections. PMID: 29094629 [PubMed - as supplied by publisher]
Source: Immunopharmacology and Immunotoxicology - Category: Allergy & Immunology Tags: Immunopharmacol Immunotoxicol Source Type: research
A 53-year-old man with B-cell non-Hodgkin lymphoma (B-NHL) presented in October 2015 with double vision, dysarthria, ataxia and mild cognitive dysfunction since 4 weeks. From February to September, he had received nivolumab as a self-initiated maintenance therapy. He had no history of autoimmune disease.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research
More News: Autoimmune Disease | Cancer | Cancer & Oncology | Databases & Libraries | Health Insurance | Hodgkin's Disease | Insurance | Lymphoma | Non-Hodgkin's Lymphoma | Rheumatology | Study | Taiwan Health